AACR 2024: Apr 7-10

AACR 2024: Apr 7-10

We are excited to be attending the American Association of Cancer Research (AACR) 2024 annual conference from April 5-10 in San Diego, California! Set up a visit with our team at Booth 939, which will be open from April 7-10, and stop by our 20 posters, which can now be added to your AACR itinerary.

AACR 2024 Poster Presentations

 Poster Title Poster Number Date & Time Location Poster Board Number
BioMice Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo 125 Apr 7, 1:30 PM – 5:00 PM Section 4 29
Validation of humanized TL1A mice for advancing preclinical research 124 Apr 7, 1:30 PM – 5:00 PM Section 4 28
Establishment of humanized CD3EDG/4-1BB mice for testing novel T cell engagers 123 Apr 7, 1:30 PM – 5:00 PM Section 4 27
Generation and validation of a novel humanized IL-31/IL-31RA/OSM/OSMR mouse model 113 Apr 7, 1:30 PM – 5:00 PM Section 4 17
Generation of humanized PD-1/PD-L1/CD94/NKG2A mice for evaluating novel combination therapies 116 Apr 7, 1:30 PM – 5:00 PM Section 4 20
TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models 1531 Apr 8, 9:00 AM – 12:30 PM Section 9 18
Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo 5339 Apr 9, 1:30 PM – 5:00 PM Section 4 19
A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies LB363 Apr 9, 1:30 PM – 5:00 PM Section 53 12
Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies LB365 Apr 9, 1:30 PM – 5:00 PM Section 53 14
Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines 5345 Apr 9, 1:30 PM – 5:00 PM Section 4 25
A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC 5346 Apr 9, 1:30 PM – 5:00 PM Section 4 26
 

 

 

 

 

 

RenBiologics









Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses LB130 Apr 8, 9:00 AM – 12:30 PM Section 52 18
A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model LB127 Apr 8, 9:00 AM – 12:30 PM Section 52 15
BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors 2724 Apr 8, 1:30 PM – 5:00 PM Section 6 15
A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation 2619 Apr 8, 1:30 PM – 5:00 PM Section 2 22
BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity 2620 Apr 8, 1:30 PM – 5:00 PM Section 2 23
BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts 2616 Apr 8, 1:30 PM – 5:00 PM Section 2 19
BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models 2618 Apr 8, 1:30 PM – 5:00 PM Section 2 21
BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy 2617 Apr 8, 1:30 PM – 5:00 PM Section 2 20
Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies 6717 Apr 10, 9:00 AM – 12:30 PM Section 3 15

 

Set Up Meetings & Secure Your Swag Bag!

We’re excited to connect with you at our posters and booth for 1:1 meetings. Use our event signup form on the left side of this page to secure your Biocytogen swag bag online, and the meeting link below to reserve a time to engage with our experts. Don’t miss out on the opportunity to receive our new swag items showcasing our sub-brands.

Limited availability, so grab yours before they’re gone!

Some Biocytogen’s RenBiologics collaborators are also going to present at AACR2024:

Syncromune’s Oral Presentation:

Title: Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Presenter: Charles J. Link, M.D.

Date: April 7, 2024

Time: 3:00 – 5:00pm PT

Session Title: Cancer Vaccines: Ready for Prime Time?

Source: GlobeNewswire | Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024

CtM Bio’s Poster Presentation

Title: A novel tri-specific T cell engager targeting the intracellular oncoprotein WT1

Poster Number: 6705

Date & Time: Apr 10, 9:00 AM – 12:30 PM

Poster Board Number: 3


The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. (Source: AACR)

Event Date: April 7-10, 2024 | Event Location: San Diego, CA

Share:

Back to top